AzTrials
AzTrials

Breast CancerOFF-MAPNCT03975179

Omitting vs. Doing Intraoperative Frozen Section Biopsy for Margin Status in Breast Conserving Surgery

A study testing Omission of intraoperative frozen section biopsy for margin status and Frozen section biopsy for margin status in people with Breast Cancer, run by Samsung Medical Center at 2 sites in South Korea.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Study phase: 3 Indication: Breast cancer patients undergoing breast conserving surgery Primary objectives: To determine the effect of selective omission of intraoperative margin evaluation via frozen section on margin positive rate Secondary objectives: To determine the effect of selective omission of intraoperative… Read more about this study

Who is it for?
Ages 19 to 70 years, women only
Conditions the study is for
Breast Cancer
What is being tested?
Omission of intraoperative frozen section biopsy for margin status and Frozen section biopsy for margin status
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,292 participants
Where
2 sitesSouth Korea
Study dates
24 Sep 2020to Jun 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 to 70 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Pathologically confirmed breast cancer by core needle biopsy with clinical stage T1-3 by American Joint Committee on Cancer(AJCC) 8th edition
  • Candidate of breast-conserving surgery
  • Daughter nodule within ≤ 1cm distance of main mass on breast MRI
  • Non-mass enhancement extent within ≤ 1cm distance of main mass on breast MRI
  • Ability to understand and willing to sign a written informed consent document : Patients who consent about deciding whether frozen biopsy will be performed by randomization

Who cannot join

  • cT4 tumors (AJCC 8th edition)
  • Cancer diagnosis confirmed by vacuum-assisted biopsy or surgical biopsy
  • Initial operation plan being total mastectomy (conversion to total mastectomy after intraoperative frozen section biopsy is acceptable)
  • Personal history of ipsilateral breast cancer
  • Ductal carcinoma in situ component on CNB result
  • Lobular carcinoma (invasive, in situ)
Show all 10Show fewer
  • Neoadjuvant chemotherapy
  • Lesion with microcalcification (microcalcification that is only contained inside the cancer mass is acceptable)
  • Multicentric tumor, however a daughter nodule within ≤ 1cm distance on breast MRI is acceptable
  • Non-mass enhancement extent wider than 1cm distance of main mass on breast MRI

Trial locations and contacts

2 sites in 1 country.

Byung Joo Chae contact

82 2 3410-3479

bj.chae@samsung.com

South Korea2 sites, 2 recruiting
  • Ilsan Paik Hospital

    Goyang-si

    Jae Il Kim

    Recruiting
  • Seoul St. Mary's Hospital

    Seoul

    Tae-Kyung Yoo, 82-2-2258-6091, robbie1025@gmail.com

    Tae-Kyung Yoo

    Recruiting

Other trials in South Korea

About this study

Official title: A Randomized Controlled Trial for Doing vs. Omitting Intraoperative Frozen Section Biopsy For Resection MArgin Status in Selected Patients Undergoing Breast Conserving Surgery

  • Study phase: 3
  • Indication: Breast cancer patients undergoing breast conserving surgery
  • Primary objectives: To determine the effect of selective omission of intraoperative margin evaluation via frozen section on margin positive rate Secondary objectives: To determine the effect of selective omission of intraoperative margin evaluation via frozen section on reoperation rate, local recurrence rate, operation time, resection volume, medical cost and patient quality-of life
  • Hypothesis: Omitting intraoperative margin evaluation via frozen section biopsy in selected breast cancer patients does not increase margin positive rate
  • Study design: Randomized controlled trial
  • Sample size: 1292 patients
  • Procedures: breast conserving surgery +/- margin frozen section biopsy (+/- additional resection)
Read the detailed description

1.1 Preoperative work-up Preoperative breast MRI is recommended to assess multifocal/centric lesions and non-mass enhancement surrounding main mass. Preoperative needle localization or skin marking is done by each hospital's method.

1.2 Surgical procedure Initial wide excision is performed as usual. The recommended target gross margin is one finger breadth. Orientation of the specimen will be done according to each center's principle. Randomization for frozen section biopsy vs. omission is done intraoperatively, after initial wide excision. For the frozen section biopsy omission group, no further procedures will be done. For the frozen section biopsy group, frozen section biopsy is performed on the specimen or cavity by the operating surgeon. The precise method is decided by the surgeon's discretion, but the recommended method is as follows. A minimum 1 x 0.5cm size of breast parenchymal tissue will be excised at minimum four directions of the specimen or cavity with a thickness of approximately 0.1cm (Figure).

Additional resection according to frozen section biopsy result will be decided by the surgeon's discretion. After review of final pathology report, decision of second operation for re-excision will also be done by surgeon's discretion. A recommendation of considering re-excision for only a positive margin (tumor on inked margin) is noted but not mandatory. Data on additional resection or re-excision must all be reported.

1.3 Pathology procedure Evaluation procedure of the frozen section biopsy specimen and wide excision, additional excision specimen is done by each hospital's method. A pathology report of both intraoperative frozen section biopsy result and final pathology result of the frozen section biopsy tissue must be done. Gross specimen measurements (height x length x depth) must be specified on pathology report. Also margin status must be recorded, positive margin defined as "no ink on tumor" for DCIS and invasive cancer. Recording of margin distance from superior, inferior, medial, lateral, margin is recommended. If all margin distance is not feasible for recording, at least margin distance of closest margin must be recorded. The final pathology result of the additional resection specimen after frozen section result must describe whether residual cancer cells were present and the site of them. This is the same for re-operation resection specimens. Thorough microscopic examination for residual cancer cells in additional/re-operation resection specimens is warranted.

1.4 Postoperative care and adjuvant therapy Postoperative care will be performed as usual. Routine adjuvant care will be given, including adjuvant radiation therapy.

1.5 Follow-up The subject's participation of this clinical trial finishes at last fill in of postoperative quality-of-life questionnaire or after last surgery.

Annual clinical examination, mammography and breast sonography is recommended for 5-year local recurrence assessment. Local recurrence is defined as pathologically confirmed ipsilateral breast tumor recurrence.

1.6 Alternatives This is a randomization between two commonly accepted surgical techniques and there is not any oncological increased risk with either. All routine precautions will be taken to minimize overall surgical risk. Alternatives to the trial would be to have standard breast conserving surgery with or without intraoperative frozen section biopsy according to surgeon's discretion and patients will be informed of this. In addition, all patients will be informed of their option for mastectomy as well.

1.7 Compensation Patients will not be paid for participating in this study. Medical expenses occurred during this study will be paid by the patient. This includes costs associated with re-operation for margin re-excision.

Conditions
Breast Cancer
Being tested
Omission of intraoperative frozen section biopsy for margin status, Frozen section biopsy for margin status
Keywords
frozen section biopsy, resection margin, breast conserving surgery
Medical subject headings
Breast Neoplasms, Margins of Excision

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Omission of intraoperative frozen section biopsy for margin statusProcedure or surgery

    Omitting intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery

  • Frozen section biopsy for margin statusProcedure or surgery

    Performing intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery

Study groups in NCT03975179
Study groupRoleWhat they receive
Frozen section omissionExperimentalIntraoperative frozen section biopsy of resection margin will not be performed
Receives: Procedure: Omission of intraoperative frozen section biopsy for margin status
Frozen sectionActive comparatorIntraoperative frozen section biopsy of resection margin will be performed. Margin evaluation of superior, medial, lateral, inferior margin is recommended but will follow surgeon's discretion.
Receives: Procedure: Frozen section biopsy for margin status

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Resection margin status

    Margin status data will be obtained from pathology report. Positive margin is defined as "no ink on tumor" for DCIS and invasive cancer. A close margin of any distance is defined as a negative margin

    Measured: 2 weeks after primary surgery

Secondary outcomes (7)
  1. Reoperation rate

    Additional operation for re-excision of margin is defined as a reoperation. The decision for a reoperation is determined by the surgeon. Data regarding reoperation and reason for reoperation must be recorded.

    Measured: 2 months after primary surgery

  2. Operation time

    Operation time is defined by time from incision to closure, which will be obtained from anesthesia report.

    Measured: Immediately after primary surgery

  3. Cost effectiveness

    Data for in-hospital cost including cost for re-excision will be collected. Opportunity cost due to elongated surgery time and labor costs from the pathology department will also be calculated and included.

    Measured: 3 months after primary surgery

  4. Resection volume

    Resected volume is calculated from gross specimen measurements of pathology report (volume = width/2 * height/2 * depth/2). When additional resection is performed, resected volumes are reported separately.

    Measured: 3 months after primary surgery

  5. Number of patients with residual cancer after reoperation

    Whether residual cancer cells are present in re-operation specimens for excision of resection margin. Thorough microscopic examinations are warranted for this endpoint.

    Measured: 3 months after primary surgery

  6. Number of patients with residual cancer after re-excision according to frozen section biopsy result

    Whether residual cancer cells are present in additional resection specimens performed according to frozen section biopsy result of resection margin. Thorough microscopic examinations are warranted for this endpoint.

    Measured: 3 months after primary surgery

  7. Patient quality-of-life assessment: BREAST-Q survey

    Quality-of-life assessment is performed by using the Korean version of the BREAST-Q survey for breast conserving therapy which is a questionnaire for patient reported outcome measurement. An assessment for physical well-being, psychosocial well-being, sexual well-being, satisfaction with breasts/outcome/care will be done. Each subscale will be reported with a scale of 0 - 100. A higher value is considered a better outcome. No total score will be calculated.

    The survey module is filled out pre- and post-operatively. Postoperative module is scored 1 month postoperatively (within one month of date of final operation but before start of radiotherapy) and within 2 months of completion of radiotherapy.

    Measured: 1 year after primary surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jun 2019
  2. Study start24 Sep 2020
  3. Primary completionJun 2023 (estimated)
  4. Study completionJun 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
1,292 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03975179
Sponsor's protocol ID
KC19EEDT0031
Acronym
OFF-MAP
Status last verified
Oct 2021
First submitted
3 Jun 2019
Last updated
21 Oct 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Raw data can be shared among co-investigators after deidentification of personal information of participated patients under request to PI.

Publications

  • Yoo TK, Kang YJ, Jeong J, Song JY, Kang SH, Lee HY, Kim ET, Yi O, Lee HB, Choi S, Park HS, Gwak G, Kim JI, Kim MK, Lee J, Kang HJ, Chae BJ. A Randomized Controlled Trial for Doing vs. Omitting Intraoperative Frozen Section Biopsy for Resection Margin Status in Selected Patients Undergoing Breast-Conserving Surgery (OFF-MAP Trial). J Breast Cancer. 2021 Dec;24(6):569-577. doi: 10.4048/jbc.2021.24.e51.

    PubMed 34979601

Questions about this trial

What is this clinical trial studying?

A study testing Omission of intraoperative frozen section biopsy for margin status and Frozen section biopsy for margin status in people with Breast Cancer, run by Samsung Medical Center at 2 sites in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Byung Joo Chae (82 2 3410-3479, bj.chae@samsung.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Resection margin status (time frame: 2 weeks after primary surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03975179, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in